跳至主要内容
临床试验/NCT01670916
NCT01670916已完成不适用

Probiotics to Prevent NEC Stage II+ in Very Preterm Infants - a Historical Control Study

Rigshospitalet, Denmark1 个研究点 分布在 1 个国家目标入组 714 人开始时间: 2010年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
714
试验地点
1
主要终点
NEC

研究概览

简要总结

Probiotics is given routinely to infants admitted to the department of neonatology during the first 3 days of life with gestational age less than 30 weeks since March 2010. The incidence of necrotizing enterocolitis Bell stage II and III will be assessed blindly from clinical records. It is hypothesised that the incidence of NEC will decrease. Infants admitted from 1 March 2010 to 28 February 2013 will be compared to infants admitted 1 Dec 2007 to 30 Nov 2009 will be compared.

研究设计

研究类型
Observational
观察模型
Case Control

入排标准

年龄范围
— 至 3 Days(Child)
性别
All
接受健康志愿者

入选标准

  • Gestational age less than 30 weeks
  • Admission during the first 3 days of life

排除标准

  • 未提供

结局指标

主要结局

NEC

时间窗: From birth until discharge home

The clinical records of infants who had a discharge diagnosis of necrotizing enterocolitis are selected. Records of infants who had a prescription of metronidazole for a non-preventive purpose is added. The clinical records are abstracted. The abstracts and X-rays are presented to a review board that are blinded to the period of birth. The board classifies the cases as NEC-I, NEC-II, NEC-III, focal intestinal perforation, and OTHER. NEC-II/III is the primary outcome.

次要结局

  • Death with NEC(Birth to discharge home)
  • Death(Birth to discharge home)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gorm Greisen

professor, consultant neonatologist

Rigshospitalet, Denmark

研究点 (1)

Loading locations...

相似试验